Omeros, a Seattle-based biopharmaceutical company with 198 employees, focuses on developing therapeutics for immunologic disorders and is advancing several candidates, including narsoplimab and OMS527, in clinical trials. The company went public on October 8, 2009.
Omeros (OMER) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Omeros's actual EPS was -$0.65, missing the estimate of -$0.58 per share, resulting in a -12.46% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
